In a significant advancement in the fight against tuberculosis (TB), India has successfully completed the genome sequencing of 10,000 Mycobacterium tuberculosis isolates. This milestone was announced by Union Science and Technology Minister Jitendra Singh, highlighting its potential to greatly improve the diagnosis and treatment of TB, particularly in cases of Multi-Drug Resistant Tuberculosis (MDR-TB).
This achievement is part of a broader initiative called Data Driven Research to Eradicate TB (Dare2eraD TB), launched in March 2022. The program includes the establishment of the Indian Tuberculosis Genomic Surveillance (InTGS) Consortium. This pan-India group is a collaboration involving the Department of Biotechnology (DBT), the Council of Scientific and Industrial Research (CSIR), the Indian Council of Medical Research (ICMR), and various clinical institutions. Their goal is to carry out whole genome sequencing on more than 32,000 TB isolates, which will help identify genetic mutations associated with drug resistance.
The sequencing work will enable researchers to catalogue existing and new resistance mutations and study how different strains of TB respond to treatment. Minister Singh described this accomplishment as a “remarkable achievement” that will help address significant treatment challenges such as treatment failures and relapses.
Recent advancements in genomic testing technology mean that doctors will soon have access to faster and more accurate ways to diagnose TB and predict drug resistance. The new testing methods could cut down the time needed for resistance profiling from weeks to just hours or days. This rapid turnaround is crucial as it allows healthcare providers to customize treatment plans tailored to individual patients based on their specific TB strain.
Rajesh Gokhale, Secretary of the DBT, stressed the importance of integrating the insights gained from this genome sequencing data into practical applications for diagnosing TB and monitoring drug resistance. He mentioned that adopting modern molecular methods for tuberculosis diagnosis remains uneven across different regions, often impacted by socioeconomic factors.
The information generated from these sequences may pave the way for innovations in TB treatment, ultimately enhancing patient care not only in India but across the globe. As health officials call for broader application of these findings, the hope is that they will help significantly reduce the burden of TB, one of the top infectious disease killers worldwide.
With these advancements, India is positioning itself at the forefront of TB research and treatment, aiming to make strides towards eradicating this long-standing health crisis.
